Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study Save Sight Registries Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study Read More »
Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration Save Sight Registries Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration Read More »
Treatment Patterns and Visual Outcomes during the Maintenance Phase of Treat-and-Extend Therapy for Age-Related Macular Degeneration Save Sight Registries Treatment Patterns and Visual Outcomes during the Maintenance Phase of Treat-and-Extend Therapy for Age-Related Macular Degeneration Read More »
Long-Term Outcomes of Treatment of Neovascular Age-Related Macular Degeneration: Data from an Observational Study Save Sight Registries Long-Term Outcomes of Treatment of Neovascular Age-Related Macular Degeneration: Data from an Observational Study Read More »
Two-year outcomes of “treat and extend” intravitreal therapy for neovascular age-related macular degeneration Save Sight Registries Two-year outcomes of “treat and extend” intravitreal therapy for neovascular age-related macular degeneration Read More »
Time to initial clinician-reported inactivation of neovascular age-related macular degeneration treated primarily with ranibizumab Save Sight Registries Time to initial clinician-reported inactivation of neovascular age-related macular degeneration treated primarily with ranibizumab Read More »
Outcomes of persistently active neovascular age-related macular degeneration treated with VEGF inhibitors: observational study data Save Sight Registries Outcomes of persistently active neovascular age-related macular degeneration treated with VEGF inhibitors: observational study data Read More »
Consequences of long-term discontinuation of vascular endothelial growth factor inhibitor therapy in the patients with neovascular age-related macular degeneration Save Sight Registries Consequences of long-term discontinuation of vascular endothelial growth factor inhibitor therapy in the patients with neovascular age-related macular degeneration Read More »
Intravitreal therapy in bilateral neovascular age-related macular degeneration Save Sight Registries Intravitreal therapy in bilateral neovascular age-related macular degeneration Read More »
Reasons for discontinuation of intravitreal vascular endothelial growth factor inhibitors in neovascular age-related macular degeneration Save Sight Registries Reasons for discontinuation of intravitreal vascular endothelial growth factor inhibitors in neovascular age-related macular degeneration Read More »
Comparison of outcomes from a phase 3 study of age-related macular degeneration with a matched, observational cohort Save Sight Registries Comparison of outcomes from a phase 3 study of age-related macular degeneration with a matched, observational cohort Read More »
Efficient capture of high-quality data on outcomes of treatment for macular diseases: the fight retinal blindness! Project Save Sight Registries Efficient capture of high-quality data on outcomes of treatment for macular diseases: the fight retinal blindness! Project Read More »
